The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology-Reference-Cited by-同舟云学术

The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology

Published:2024-04-22 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Sorce G.,Stabile A.^ORCID,Pellegrino F.,Mazzone E.,Mattei A.,Afferi L.,Serni S.,Minervini A.,Roumiguiè M.,Malavaud B.,Valerio M.,Rakauskas A.,Marra G.,Gontero P.,Porpiglia F.,Guo H.,Zhuang J.,Gandaglia G.,Montorsi F.,Briganti A.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-04963-w.pdf

Reference30 articles.

1. (2022) EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam (ISBN 978-94-92671-16-5)

2. Sorce G, Flammia RS, Hoeh B et al (2022) Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. Prostate. https://doi.org/10.1002/PROS.24349

3. Bullock N, Simpkin A, Fowler S, Varma M, Kynaston H, Narahari K (2019) Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British association of urological surgeons radical prostatectomy registry. BMC Urol. https://doi.org/10.1186/S12894-019-0526-9

4. Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024. https://doi.org/10.1016/J.EURURO.2012.01.050

5. Hoeh B, Flammia R, Hohenhorst L et al (2022) Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate Int 10(1):21–27. https://doi.org/10.1016/J.PRNIL.2022.01.004